Skip to main content
OpenTrials
Completed

NCT Number: NCT07191665

Explore the Use of Cortical Oxygenation Measures in Nutrition Research

The current project aims to explore the use of cortical oxygenation measures obtained with functional Near Infrared Spectroscopy (fNIRS) in acute nutrition interventions with outcomes on cognition.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–35 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinical Innovation Lab

Lausanne, Canton of Vaud, 1000, Switzerland

About this study

The project aims to test a previously developed fNIRS-based protocol for evaluating the acute effects of dietary components on cognitive function in a population of healthy young adults. The testing will involve detecting patterns in fNIRS-based cortical tissue oxygenation level and cognitive performance that are expected due to the bioactive mechanisms of the studied components.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and Females 25-35 years old
  • BMI between 18.5 kg/m2 and 29.9 kg/m2
  • Conditions for study procedure compliance:
  • Willing and able to sign an informed consent form
  • Fluent in English (self-reported C1 or C2 English level)
  • Have reliable cortical oxygenation signal for subsequent analysis (based on the real-time computation of a parameter reflecting the quality of the signal, which may be influenced by variations in hair thickness)
  • Dominant right-handed
  • Have normal or corrected-to-normal vision
  • Willing and able to comply with the protocol requirements

Exclusion criteria

  • Conditions that may affect cortical oxygenation:
  • Have a past or current neural, cerebrovascular, cardiovascular, or respiratory disease (based on anamnesis)
  • Have a past or current kidney disease or condition (based on anamnesis)
  • Measured hypo- or hyper-tension (verified by evaluating Blood Pressure, BP, measure against medical norms at screening)
  • Self-reported, suspected or diagnosed migraine (based on anamnesis)
  • Have a mild or clinical form of insomnia (verified by thresholding rated insomnia severity index, ISI, at or above 8) or being a night shift worker (based on anamnesis)
  • Regular smoker, regularly is being defined as more than 2 cigarettes per week
  • Participating in vigorous physical activity defined as requiring more than 6 metabolic equivalents (e.g., hiking, jogging at 10 km/h or more, carrying of heavy loads, bicycling fast at 23 km/h or more, basketball, soccer, and tennis single), greater than 4 times 45 minutes per week
  • Conditions that may affect cognition or mental fatigue:
  • Have a current psychiatric disorder or have a self-reported, suspected or diagnosed anxiety or depression (based on anamnesis)
  • Taking illicit drugs for e.g., cannabis, heroin, and cocaine
  • Have an average alcohol consumption defined as greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
  • Pregnant (verified by a pregnancy test in urine dipstick format provided by the study's site) or seeking to become pregnant or breast feeding (based on anamnesis)
  • Conditions that may interact with the IP mechanism:
  • Have food allergies and intolerances (based on anamnesis)
  • Have a high usual consumption of caffeine-based beverages and foods (verified by thresholding the daily consumption of caffeine as determined by the Caffeine Consumption Questionnaire, CCQ, at or above 600mg)
  • Body mass below 60kg (associated with a dosing of more than 3mg caffeine per 1kg of body mass)
  • Currently taking Sildenafil (based on anamnesis)
  • Self-reported, suspected or diagnosed with acute inflammatory diseases e.g., herpes simplex virus, allergies, or asthma (based on anamnesis)
  • Have a hierarchal or family relationship with any of the research team members.
  • Currently participating in an interventional study.

Treatment and study plan

Acute nutrition intervention

Other

The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.

Primary outcomes

  1. Caffeine-induced pattern of correlation between cortical tissue oxygenation and cognitive performance (relative to placebo).

    Time frame: Change in correlation from baseline to 45' post-product intake ; This measurement is performed for each product. Each product is given a single time. 5-9 days between each of the products assigned.

    Detect a pattern of correlation between caffeine-induced changes in cortical tissue oxygenation and cognitive performance. Cognitive performance will be assessed using accuracy and reaction time data collected from cognitive tests, such as memory tests.

  2. Caffeine-induced pattern of correlation between cortical tissue oxygenation and cognitive performance (relative to placebo)

    Time frame: Change in correlation from baseline to 45' post-product intake ; This measurement is performed for each product. Each product is given a single time. 5-9 days between each of the products assigned.

    Detect a pattern of correlation between caffeine-induced changes in cortical tissue oxygenation and cognitive performance. Cortical tissue oxygenation level will be measured by analyzing changes in oxygenated or deoxygenated hemoglobin concentration.

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Collaborators

  • Ecole Polytechnique Fédérale de Lausanne

Registry information

Official study title

Exploring Cortical Oxygenation Modulations in Response to Dietary Components During Cognitive Activity in Healthy Adults: a fNIRS Study

Acronym: Saga

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Sep 25, 2025
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.